FLUIDDA-led Consortium secures 1MEUR for Lung Transplant Research

February 11, 2014

KONTICH, Belgium, February 11, 2014 /PRNewswire/ –

The Flemish agency for Innovation by Science and Technology (IWT) has awarded a
consortium led by the Belgian-based company FLUIDDA a grant of 1MEUR to conduct research
to increase survival rates after lung transplantation through Functional Respiratory
Imaging (FRI). The international consortium includes, besides FLUIDDA and its long-term
research partner Materialise (Leuven, Belgium), also the University of Antwerp (Antwerp,
Belgium), Columbia University Medical Center (New York, USA) and the University of
Pennsylvania Medical Center (Philadelphia, USA).

Only 50% of the patients receiving lung transplantation reach 5-year survival. The
major cause of mortality is the rejection of the transplanted organ. The current lung
function tests are often not sensitive enough to detect the early signs of rejection.

Functional Respiratory Imaging (FRI), a state-of-the-art technology developed by
FLUIDDA, has the potential to detect signs of rejection in an early stage, thereby
increasing the chance of survival through better therapy. The funding will be used to
support the technical developments and proof of concept (POC) clinical studies. When the
results are positive, the scope of the project will be expanded through collaborations
with additional clinical centers and industrial partners to offer the technology on a
larger scale.

FLUIDDA’s CEO Dr. Jan De Backer states: “This project is very important for us and our
partners as it could result in the first application of our FRI technology in the clinical
practice, providing in a significant benefit for many patients. Until now FRI has been
successfully used in drug development for respiratory diseases such as asthma and COPD.”

MATERIALISE department director Dr. Koen Engelborghts states: “FRI is a nice example
of how new technologies for engineering on anatomy are being developed using the Mimics
Innovation Suite. We’re excited and confident about applying our know-how in order to take
this a step further and bring engineering on anatomy into the clinic.”

About FLUIDDA (http://www.FLUIDDA.com)

FLUIDDA is the world leader in the field of Functional Respiratory Imaging (FRI)
research and development. The company’s proprietary FRI technology offers pharmaceutical
companies and healthcare providers a unique entry point into personalized medicine for
patients suffering from respiratory diseases and sleep-related breathing disorders.
Implementation of FRI in the clinical practice creates significant added value to the
current healthcare standard in the respiratory field.


Source: PR Newswire

comments powered by Disqus